MRIdian SMART: Treat and Prove What Others Can’t
At ViewRay, we believe in the value of clinical studies, and support sponsored and investigator-initiated research studies.
Definition of Clinical Success
5 or Fewer
No to Low Grade 3 Toxicity
Ongoing Clinical Research
In addition to our sponsored study, ViewRay has a robust investigator-initiated research (IIR) program supporting clinical and technical projects. For more information, please visit our IIR page. Additionally, please see the list of publicly referenced clinical, prospective, phase I, II, or III studies below.
Stereotactic Magnetic Resonance Imaging (MRI) Guided On-table Adaptive Radiation Therapy (SMART) for Patients With Borderline or Inoperable Locally Advanced Pancreatic Cancer, ViewRay sponsored, https://ClinicalTrials.gov/ct2/show/NCT03621644 [Active, not recruiting]
This trial is designed to assess the primary objective of grade 3 or greater GI toxicity at 90 days for patients with borderline resectable or inoperable locally advanced pancreatic cancer treated with MRI-guided on-table adaptive radiation therapy and soft tissue tracking with radiation beam gating to 50 Gy in 5 fractions.
Locally Advanced Pancreatic Cancer Treated with ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy (LAP-ABLATE), ViewRay sponsored, https://ClinicalTrials.gov/ct2/show/NCT05585554
This is a prospective, randomized controlled trial (2:1) comparing induction chemotherapy followed by ablative Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) versus chemotherapy alone in locally advanced pancreatic cancer patients. Overall survival outcomes at 2-years will be evaluated.
Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy (ARCADE), Anna Bruynzeel, MD, PhD, Amsterdam UMC, Amsterdam, Netherlands, https://ClinicalTrials.gov/ct2/show/NCT04881487
A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'trials within cohorts' (TwiCs) design in which the effect of additional local ablative therapy compared to current standard of care alone, on survival after recurrence in patients with isolated local pancreatic ductal adenocarcinoma (PDAC) recurrence. The most important secondary endpoint is quality of life.
Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival After Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation (CROSSFIRE), Anna Bruynzeel, MD, PhD, Amsterdam UMC, Amsterdam, Netherlands, https://ClinicalTrials.gov/ct2/show/NCT02791503
The primary aim of the CROSSFIRE trial is to compare the efficacy (in terms of overall survival) of FOLFIRINOX and IRE (experimental arm) to the efficacy of FOLFIRINOX and stereotactic ablative radiotherapy (SABR) (control arm) in patients with locally advanced, non-resectable, non-metastasized, pancreatic cancer (LAPC).
Preoperative Radiotherapy in Patients at Very High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy (FIBROPANC), Annelie Suurmeijer, MD, PhD, Amsterdam UMC, Amsterdam, Netherlands, https://clinicaltrialregister.nl/en/trial/21296
The hypothesis is that a single course of 12Gy preoperative radiotherapy may lead to sufficient fibrosis in a small (4cm) targeted area of pancreatic tissue where the anastomosis with either the jejunum will be created, thereby reducing the risk of grade B and C POPF in patients at high risk of developing this complication after pancreatoduodenectomy.
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer, Michael Chuong, MD, Miami Cancer Institute, Miami, Florida, United States, https://ClinicalTrials.gov/ct2/show/NCT05679674
The purpose of this clinical trial is to determine whether using chemotherapy followed by stereotactic ablative body radiation therapy (SABR) and tumor treating fields (TTF) will slow tumor growth in people with locally advanced pancreas cancer. All participants will receive SABR therapy once per day for five days and use the TTF system for at least 18 hours per day starting on the first day of SABR until the tumor progresses or severe toxicity develops.
Evaluation of Hypofractionated Adaptive Radiotherapy Using the MR Linac in Localised Pancreatic Cancer, Somnath Mukherjee, MD, University of Oxford, Oxford, UK, https://isrctn.com/ISRCTN10557832
This trial is to establish the safety of MR-guided hypofractionation stereotactic body radiotherapy (SBRT) in localised pancreatic cancer. There are three arms: 5, 3 or 1-fraction MR-guided stereotactic radiotherapy over 1-3 weeks. The assigned choice is dependent on the order the patient is referred.Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma, Hyun Kim, MD, Washington University School of Medicine, Saint Louis, Missouri, United States, https://ClinicalTrials.gov/show/NCT04331041
Patients with advanced pancreas adenocarcinoma will be treated with standard of care chemotherapy followed by stereotactic body radiotherapy (SBRT) concurrent with the focal adhesion kinase (FAK) inhibitor and assessed for clinical outcomes such as progression free survival (PFS), local control, distant control, and toxicity in this study.
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer (LAPTOP), Inna Chen, MD, Herlev & Gentofte University Hospital, Herlev, Denmark, https://ClinicalTrials.gov/show/NCT04247165
This study is to explore the safety and synergy of the proposed combinatorial approach, participants with locally advanced PC will receive nivolumab and ipilimumab administered in combination with gemcitabine and nab-paclitaxel followed by immune-chemoradiation.
Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients (PANCOSAR), Anna Bruynzeel, MD, PhD, Amsterdam UMC, Amsterdam, Netherlands, https://ClinicalTrials.gov/ct2/show/NCT05265663
This multicenter randomized controlled trial is to investigate the potential benefit in survival and quality of life after SABR in patients with localized PDAC for whom no other treatment is available, as compared to controls managed with best supportive care.
MR-Guided Adaptive Stereotactic Body Radiotherapy (SBRT) of Primary Tumor for Pain Control in Metastatic Pancreatic Ductal Adenocarcinoma (MASPAC), Maximilian Niyazi, MD, MSc, University of Munich, Munich, Bavaria, Germany, https://ClinicalTrials.gov/ct2/show/NCT05114213
The MASPAC trial investigates the added benefit of MR-guided adaptive SBRT of the primary tumor embedded between standard chemotherapy cycles for pain control and prevention of pain in patients with metastatic PDAC (mPDAC).
Preoperative MR-Guided Radiation Therapy in Gastric Cancer, Hyun Kim, MD, Washington University School of Medicine, Saint Louis, Missouri, United States, https://ClinicalTrials.gov/show/NCT04162665
Patients with locoregional gastric adenocarcinoma will receive hypofractionated magnetic resonance guided radiotherapy followed by chemotherapy followed by surgery and pathologic complete response (pCR) rate will be quantified in this study.
Prospective Evaluation of the Safety and Efficacy of MR-guided Single-fraction Stereotactic Ablative Radiotherapy for Unresectable Primary or Secondary Liver Tumors - SINGLE SHOT LIVER, Stefanie Corradini, MD, Ludwig Maximilian University of Munich, Munich, Germany, https://drks.de/search/en/trial/DRKS00027117
Patients with unresectable primary or secondary liver tumors who will receive single-fraction MR-guided stereotactic ablative radiotherapy.
Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver, Signe Normann Risum, MD, PhD, Rigshospitalet, Denmark, https://ClinicalTrials.gov/ct2/show/NCT03654131
This study is a randomized phase II trial between microwave ablation (MWA) and stereotactic body radiotherapy (SBRT) - two standard treatment modalities for colorectal patients with metastatic disease in the liver.
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors (RASTAF), Magali Rouffiac Thouant, MD, & Emlie Rederstorff, PhD, Centre Georges François Leclerc, Dijon, France, https://ClinicalTrials.gov/show/NCT04242342
This is a phase II adaptative magnetic resonance-guided stereotactic body radiotherapy (SBRT) study for treatment of primary or secondary progressive liver tumors.
OAR-Based, Dose Escalated SBRT with Real Time Adaptive MRI Guidance for Liver Metastases, Michael Bassetti, MD, PhD, University of Wisconsin, Madison, Wisconsin, United States, https://ClinicalTrials.gov/ct2/show/NCT04020276
This trial is to identify a safe maximum tolerated dose level for magnetic resonance image (MRI)-guided stereotactic body radiotherapy (SBRT) treatment of bowel and liver metastases, respectively.
Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases (MAESTRO), Jürrgen Debus, MD, PhD, University Hospital Heidelberg, Heidelberg, Germany, https://ClinicalTrials.gov/ct2/show/NCT05027711
The MAESTRO trial aims to assess the potential advantages of adaptive, gated MR-guided SBRT (MRgSBRT) compared to conventional SBRT at a standard linac using an ITV (internal target volume) approach (ITV-SBRT), in patients with liver metastases.
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (SMART TNT), Lorraine Portelance, MD, University of Miami, Miami, Florida, United States, https://ClinicalTrials.gov/ct2/show/NCT05412082
The purpose of this research study is to find out how safe and effective is treating patients with locally advanced rectal cancer (LARC) with chemotherapy first and then follow with radiation therapy to a higher dose than what is usually delivered and see if patients could have complete response and be spared from surgery.
THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy (THUNDER2), Giuditta Chiloiro, MD, PhD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, https://ClinicalTrials.gov/ct2/show/NCT04815694
This trial is to investigate the impact of dose escalation in rectal cancer, identifying the poor responder cases using the ERI index during the course of radiotherapy and increasing the prescribed dose in these patients.
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma, Jessica M Frakes, MD & Seth Felder, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States, https://ClinicalTrials.gov/ct2/show/NCT05108428
The purpose of this study is to determine the feasibility of using magnetic resonance imaging (MRI)-guided adaptive chemoradiation therapy to improve response to treatment, in patients with locally advanced rectal adenocarcinoma.
CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study, Amar Kishan, MD, UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States, https://ClinicalTrials.gov/show/NCT04384770 [Active, not recruiting]
This is a phase III randomized trial designed to evaluate the superiority of magnetic resonance imaging (MRI)-guided stereotactic body radiotherapy (SBRT) over standard computed tomography (CT)-guided SBRT for prostate cancer (PCa) with respect to acute physician-scored genitourinary (GU) toxicity.
Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy (SCIMITAR), Amar Kishan, MD, UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States, https://ClinicalTrials.gov/ct2/show/NCT03541850 [Active, not recruiting]
This phase II trial is studying how well stereotactic body radiation therapy works in treating patients with prostate cancer that has not spread to other parts of the body and have undergone surgery.
PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT), Himanshu Nagar, MD, Weill Medical College of Cornell University, New York, New York, United States, https://ClinicalTrials.gov/ct2/show/NCT03663218
Patients with a diagnosis of high-risk prostate cancer with a Gleason score of 8 or greater are eligible for this trial. The study will enroll 20 subjects in 3 years. This is a single arm study, and the primary objectives is to assess if a patient can undergo a radical prostatectomy after SBRT without a post-operative grade 3 or higher toxicity at 30 days.
Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma (STEREO-RML), Magali Quivrin, Centre Georges Francois Leclerc, Dijon, France, https://ClinicalTrials.gov/ct2/show/NCT04909294
This phase II multicenter trial is evaluating the efficacy and safety of a stereotaxic prostatic radiotherapy delivered on Linac MRI, with integrated boost in the case of an index tumor, in patients with prostate adenocarcinoma.
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy (EXCALIBUR), Amar Kishan, MD, UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States, https://ClinicalTrials.gov/ct2/show/NCT04915508
This phase II trial investigates the effect of extremely hypofractionated intensity-modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate-specific antigen (PSA) after radical prostatectomy.
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer, Ariel Marciscano, MD, Weill Cornell Medicine, New York, New York, United States, https://ClinicalTrials.gov/show/NCT04402151
Patients will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance (MR) prior to start of the radiation treatment planning process and will be evaluated for recurrence free survival in this study.
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer in 4 Weeks v. 2 Weeks (SHORTER) Himanshu Nagar, MD, Weill Cornell Medicine, New York, New York, United States, https://ClinicalTrials.gov/ct2/show/NCT04422132
This study will compare urinary and bowel side effects of hypofractionated radiotherapy in 20 treatments (4 weeks) to ultra-hypofractionated radiotherapy in 5 treatments (2 weeks) for prostate cancer that has returned after prostatectomy and evaluate time to progression and the quality of life.
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer (FORT), Himanshu Nagar, MD, Weill Medical College of Cornell University, New York, New York, United States, https://ClinicalTrials.gov/ct2/show/NCT04984343
This randomized phase II study is to compare 5 radiation therapy treatments to 2 radiation therapy treatments in men with low or intermediate-risk prostate cancer.
Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE), Timothy McClure, MD, Weill Medical College of Cornell University, New York, New York, United States, https://ClinicalTrials.gov/ct2/show/NCT05345444
This is a single-site feasibility trial with favorable intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT. The investigators hypothesize that the combined therapy will feasible and be safe to perform with low morbidity.
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer, Ariel Marciscano, MD, Weill Medical College of Cornell University, New York, New York, United States, https://ClinicalTrials.gov/ct2/show/NCT04220983
This trial is to demonstrate the safety and feasibility of using 36.25 Gy in 5 fractions, plus a simultaneous integrated boost (when indicated), in patients with metastatic prostate cancer.
Stereotactic MRI-guided Radiation Therapy for Localized prostatE Cancer (SMILE), Stefan Körber, MD, University Hospital Heidelberg, Heidelberg, Germany, https://ClinicalTrials.gov/ct2/show/NCT04845503
This prospective, non-randomized, multicentric, Phase II SMILE study is to test whether the MRI-guided radiotherapy with a greatly shortened radiotherapy of the prostate over 5 radiation sessions is possible and safe.
MR-guided Prostate Stereotactic Body Radiotherapy in Seven Days (Proseven), Mark De Ridder, MD, Universitair Ziekenhuis Brussel, Brussels, Belgium, https://ClinicalTrials.gov/ct2/show/NCT04896801
The Proseven trial is a prospective interventional study that will evaluate the toxicity and efficacy of MR-guided stereotactic body radiotherapy (SBRT) in the profound hypofractionated treatment of prostate cancer. Patients will be treated in 5 daily fractions within a short overall treatment time (OTT) of 7 days.
Pulmonary Magnetic Resonance-guided Online Adaptive Radiotherapy of Locally Advanced Non-Small Cell Lung Cancer (PUMA), Jürrgen Debus, MD, PhD, University Hospital Heidelberg, Heidelberg, Germany, https://ClinicalTrials.gov/ct2/show/NCT05237453
This clinical trial aims to demonstrate the feasibility of MR-guided online ART to locally-advanced NSCLC.
Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable State IIB and IIIA Non-small Cell Lung Cancer, Gregory Vlacich, MD, PhD, Washington University School of Medicine, St. Louis, Missouri, United States, https://ClinicalTrials.gov/ct2/show/NCT03916419
This prospective, single-arm, phase II clinical trial with safety lead-in will test the feasibility and outcomes of magnetic resonance (MR)-guided radiation therapy system and apply principles of hypofractionation toward the current treatment paradigm of concurrent chemoradiation and consolidation immunotherapy for locally advanced non-small-cell lung cancer (NSCLC).
Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location (MAGELLAN), Juliane Hörner-Rieber, MD, University Hospital of Heidelberg, Heidelberg, Germany, https://ClinicalTrials.gov/ct2/show/NCT04925583
MAGELLAN is a phase-I dose escalation trial that aims to identify the maximum tolerated dose (MTD) of MR-guided SBRT of ultracentral lung Tumors (primary objective).
Study of LUNG Stereotactic Adaptive Ablative Radiotherapy (LUNG STAAR), Rupesh Kotecha, MD, Miami Cancer Institute, Miami, Florida, United States, https://ClinicalTrials.gov/ct2/show/NCT04917224
The proposed study expands on the principles of SBRT (Stereotactic Body Radiation Therapy) and SABR (Stereotactic Ablative Radiotherapy) for centrally located NSCLC (Non-Small Cell Lung Cancer) to further optimize outcomes in this patient population with utilization of the adaptive workflow to maintain tumor control rates but decrease the incidence and grade of treatment-related toxicities.
A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY), (STRICTSTARLUNG), Mette Pøhl, MD, PhD, Rigshospitalet, Copenhagen, Denmark, https://ClinicalTrials.gov/ct2/show/NCT05354596
An open-label phase II study, investigating toxicity, treatment efficacy and the local tumor control rate in 69 patients with centrally located tumors and in 69 patients with ultra-centrally located tumors in the lung. Ultra-centrally tumors are treated on MR-linacs with daily MR-guided plan-adaptation.
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer, Jonathan Leeman, MD, Brigham and Women's Hospital, Boston, Massachusetts, United States, https://ClinicalTrials.gov/ct2/show/NCT04789486
This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and lung tumors.
Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients (ABLATIVE-2), Desirée van den Bongard, MD, PhD, Amsterdam UMC, Amsterdam, Netherlands, https://ClinicalTrials.gov/ct2/show/NCT05350722
In this ABLATIVE-2 trial, low-risk breast cancer patients will be treated with MRI-guided single dose preoperative partial breast radiotherapy to assess the rate of pathologic complete response after an interval of six to twelve months between radiotherapy and surgery. Response monitoring will be assessed using MRI and markers in blood and tumor tissue to enable prediction of pathologic response.
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer, Bethany Anderson, MD, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States, https://ClinicalTrials.gov/show/NCT03936478
This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer.
Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma, Imran Zoberi, MD, & William Kennedy, MD, Washington University School of Medicine, Saint Louis, Missouri, United States, https://ClinicalTrials.gov/show/NCT03612648
This single institution, phase I/II study is designed primarily to evaluate three fractions accelerated partial breast irradiation as the sole method of radiation therapy for low-risk stage 0 and I breast carcinoma.
Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma (BreaStBRT), Imran Zoberi, MD, Washington University School of Medicine, Saint Louis, Missouri, United States, https://ClinicalTrials.gov/ct2/show/NCT04849871
This study will evaluate the local control, complication rates, cosmetic results, and quality of life between patients treated with a single fraction vs. five fractions of accelerated partial breast irradiation (S_APBI vs. F_APBI) when used as the sole method of radiation therapy.
Response Assessment During MR-guided Radiation Therapy for Glioblastoma (MARGA), Nicolaus Andratschke, MD, University of Zurich, Zurich, Switzerland, https://ClinicalTrials.gov/ct2/show/NCT05565326
The study seeks to assess the response of glioblastoma multiforme to treatment using weekly low field (0.35 T) MR-images of the brain at a MRIdian linac system during standard radiotherapy at the same system. A total of 20 patients in a single arm will be recruited for this investigation.
Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine, Clifford Robinson, MD, Washington University School of Medicine, Saint Louis, Missouri, United States, https://ClinicalTrials.gov/show/NCT03878485
This study will evaluate short-term goals of workflow feasibility and safety of same-session magnetic resonance (MR)-only simulation and treatment planning, on-table, using stereotactic magnetic resonance image (MRI)-guided adaptive radiotherapy (SMART).
Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine, Lauren Henke, MD, M.S.C.I., Washington University School of Medicine, Saint Louis, Missouri, United States, https://ClinicalTrials.gov/show/NCT03878485
This study will evaluate short-term goals of workflow feasibility and safety of same-session magnetic resonance (MR)-only simulation and treatment planning, on-table, using stereotactic magnetic resonance image (MRI)-guided adaptive radiotherapy (SMART).
MARTHA-trial: MRI – Guided Adaptive RadioTHerapy for Reducing XerostomiA in Head and Neck Cancer Including Longitudinal Evaluation of the Patient’s Immune Profile Under Radiotherapy, Panagiotis Balermpas, MD, Zurich University Hospital, Zurich, Switzerland, https://ClinicalTrials.gov/show/NCT03972072
This prospective, phase II trial is to evaluate xerostomia after magnetic resonance image (MRI)-guided adaptive radiotherapy of head and neck cancer.
SHARP Trial - Stereotactic Heart Ablative RadiotheraPy Prospective Observational Study of MR-guided Stereotactic Ablative Radiotherapy of Inoperable Primary or Recurrent Malignant Cardiac Sarcomas or Cardiac Metastases, Stefanie Corradini, MD, Ludwig Maximilian University of Munich, Munich, Germany, https://drks.de/search/en/trial/DRKS00027108
The goal of this prospective multicentric observational study is to investigate the feasibility, toxicity and outcome of magnetic resonance-guided stereotactic body radiation therapy (MR-guided SBRT).
Habitat Escalated Adaptive Therapy (HEAT), with Neoadjuvant Radiation for Soft Tissue Sarcoma, Arash O Naghavi, MD, MS, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States, https://ClinicalTrials.gov/ct2/show/NCT05301283
The purpose of the study is to utilize radiomic images to precisely locate areas of tumor that can be treated with dose escalation radiation therapy.
Hypofractionated Radiotherapy for Soft Tissue Sarcomas, Zachary Morris, MD, PhD, University of Wisconsin, Madison, Wisconsin, United States, https://ClinicalTrials.gov/ct2/show/NCT03972930 [Active, not recruiting]
Participants will be treated with 3-8 fractions, with the maximum prescribed dose to the Planning Tumor Volume (PTV) volume being 60 Gy delivered over a period of at most 8 weeks.
Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma, Michael Chuong, MD, Miami Cancer Institute, Miami, FL, United States, https://ClinicalTrials.gov/show/NCT04376502
This is an open-label, single arm, phase II clinical trial in patients with metastatic solid malignancy of any histology who have previously experienced limited progression in at least 1 and up to 5 lesions while on immune checkpoint inhibitors monotherapy.
SMART Master Protocol, Stereotactic Magnetic Resonance Guided Radiation Therapy, Jonathan Leeman, MD, Brigham & Women’s Hospital, Boston, Massachusetts, United States, https://ClinicalTrials.gov/show/NCT04115254
This is a master prospective Phase I-II trial evaluating the feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
CONFIRM: Magnetic Resonance Guided Radiation Therapy, Raymond Mak, MD, Brigham & Women’s Hospital, Boston, Massachusetts, United States | Dana Farber Cancer Institute, Boston, Massachusetts, United States, https://ClinicalTrials.gov/show/NCT04368702
This is a master clinical protocol evaluating magnetic resonance (MR) image-guided radiation in patients with gastric and breast cancer.
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction (SMART ONE), Michael Chuong, MD, Miami Cancer Institute, Miami, Florida, United States, https://ClinicalTrials.gov/ct2/show/NCT04939246
This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph node, pancreas, and/or kidney.
SOFT- Stereotactic Ablative Radiotherapy of Infra-diaphragmatic Soft Tissue Metastases (SOFT), Mette Felter, MD, Herlev Hospital, Herlev, Denmark, https://www.ClinicalTrials.gov/ct2/show/NCT04407897
This prospective phase II multicenter-study will evaluate the feasibility and safety of MR-guided stereotactic ablative radiotherapy (SABR) for infra-diaphragmatic soft tissue metastases.
The MRIdian linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. Medical information services provides support for medical, scientific, and technical information in response to inquiries regarding the use of ViewRay products. Contact our Medical Affairs team at [email protected] for more information.